Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.
Researchers pooled individual participant-level data from trials of chronic kidney disease and type 2 diabetes and a trial of heart failure to compare risks between men and women with cardiovascular-kidney-metabolic syndrome. Findings indicated women were slightly older and less likely to receive common CKM therapies. During follow-up, both groups had similar risks of HF hospitalization or cardiovascular death, but women had lower all-cause mortality. Finerenone showed consistent benefits in both sexes.
What to check after reading
The study highlights persistent sex-based disparities in CKM care, although finerenone was effective in both men and women.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.